Corticosteroids in Patients Hospitalized with Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis

Clinical Infectious Diseases

Volumn 66, Issue 3, 2018, Pages 346-354

  Briel, Matthias ^a,b   Spoorenberg, Simone M C ^c   Snijders, Dominic ^d   Torres, Antoni ^e   Fernandez Serrano, Silvia ^f   Meduri, G Umberto ^g,h   Gabarrús, Albert ^e   Blum, Claudine A ^i,j   Confalonieri, Marco ^g   Kasenda, Benjamin ^a   Siemieniuk, Reed A C ^b,k   Boersma, Wim ^l   Bos, Willem Jan W ^c   Christ Crain, Mirjam ⁱ  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MCMASTER UNIVERSITY   (Canada)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d Infection and Immunology   (Netherlands)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g UNIVERSITY OF TRIESTE   (Italy)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j Medical University Clinic   (Switzerland)

^k UNIVERSITY OF TORONTO   (Canada)

^l Noordwest Hospital Alkmaar   (Netherlands)

more..

Author keywords

community acquired pneumonia; corticosteroids; individual patient data metaanalysis; randomized clinical trials

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE;

COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; EMBASE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LENGTH OF STAY; LOW DRUG DOSE; MEDLINE; META ANALYSIS; PATIENT CODING; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; AGE; COMMUNITY ACQUIRED INFECTION; MORTALITY; ODDS RATIO; PNEUMONIA; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; AGE FACTORS; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; LENGTH OF STAY; ODDS RATIO; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85041197226     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix801     Document Type: Review

References (32)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015; 385:117-71.
2. Sogaard M, Nielsen RB, Schonheyder HC, Norgaard M, Thomsen RW. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997-2011. Respir Med 2014; 108:1214-22.
3. Cavallazzi R, Wiemken T, Arnold FW, et al. Outcomes in patients with community- acquired pneumonia admitted to the intensive care unit. Respir Med 2015; 109:743-50.
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67:71-9.
5. Kellum JA, Kong L, Fink MP, et al.; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167:1655-63.
6. Remmelts HH, Meijvis SC, Biesma DH, et al. Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia. Clin Vaccine Immunol 2012; 19:1532-8.
7. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015; 163:519-28.
8. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-8.
9. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313:677-86.
10. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double- blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975-82.
11. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2005; 2:209-17.
12. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2011; 3:CD007720.
13. El-Ghamrawy AH, Shokeir MH, Essmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest Dis Tuberc 2006; 55:91-9.
14. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 2013; 62:439-45.
15. Sabry NA, Omar EED. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacology & Pharmacy 2011; 2:73-81.
16. Bassler D, Briel M, Montori VM, et al.; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180-7.
17. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ; GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995-8.
18. Kasenda B, Sauerbrei W, Royston P, et al. Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. BMJ Open 2016; 6:e011148.
19. Sauerbrei W, Royston P. A new strategy for meta-analysis of continuous covariates in observational studies. Stat Med 2011; 30:3341-60.
20. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo- controlled trial. Lancet 2015; 385:1511-8.
21. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15:R96.
22. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:2023-30.
23. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004; 66:411-21.
24. Koopman L, van der Heijden GJ, Glasziou PP, Grobbee DE, Rovers MM. A systematic review of analytical methods used to study subgroups in (individual patient data) meta-analyses. J Clin Epidemiol 2007; 60:1002-9.
25. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3: iii1-55.
26. Mandell LA, Wunderink RG, Anzueto A, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27-72.
27. Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2015; 10:e0144032.
28. Horita N, Otsuka T, Haranaga S, et al. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep 2015; 5:14061.
29. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993; 104:389-92.
30. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007; 297:468-70.
31. Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 2016; 149:209-19.
32. Remmelts HH, Meijvis SC, Heijligenberg R, et al. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia. J Infect 2012; 65:25-31.